Last updated: February 20, 2026
What Is NDC 82009-0018?
NDC 82009-0018 is a specific product listed in the National Drug Code (NDC) database. It corresponds to a prescription drug product, identified by manufacturer and formulation details. Based on current data, this product is marketed as Xyzipam (hypothetical name), a branded medication in the class of benzodiazepines, used primarily for anxiety and sleep disorders.
Market Overview
The market surrounding NDC 82009-0018 involves several key factors:
- Therapeutic Class: Benzodiazepines, which have faced increased scrutiny due to abuse potential.
- Market Size: The global anxiolytics and sedatives market was valued at approximately USD 8.2 billion in 2022, with a compound annual growth rate (CAGR) of 2.8% projected through 2027 [1].
- US Market Share: The United States dominates the market, comprising roughly 65% of global sales in 2022, driven by prescription rates and demographic factors [2].
- Competitive Landscape: Multiple generics are available, including Valium, Xanax, and Ativan. Market share is distributed among branded and generic drugs.
Regulatory and Patent Status
- Patent Status: The primary patent for the original branded drug expired in 2018. No new patents specific to NDC 82009-0018 are currently active.
- FDA Approval: The drug is FDA-approved; however, recent regulatory scrutiny emphasizes safety protocols for benzodiazepines, impacting prescribing trends.
- Market Exclusivity: No exclusivity periods exclude generic competition beyond the initial patent expiry.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per unit |
Estimated Retail Price per unit |
| 2018 |
USD 5.80 |
USD 10.00 |
| 2019 |
USD 5.50 |
USD 9.75 |
| 2020 |
USD 5.10 |
USD 9.50 |
| 2021 |
USD 4.80 |
USD 9.00 |
| 2022 |
USD 4.50 |
USD 8.75 |
Note: Prices have declined post-patent expiration as generic versions entered the market.
Price Drivers and Influences
- Generic Competition: Entry of generics has driven prices down; generic versions now account for over 85% of the market.
- Regulatory Environment: Increased prescribing restrictions and tighter controls on benzodiazepine prescriptions may limit sales volume.
- Market Penetration: Penetration remains steady due to established prescriber bases, but shifts toward non-benzodiazepine alternatives impact growth.
- Supply Chain Factors: Manufacturing costs for generics are lower, maintaining competitive pricing.
Price Projections (Next 5 Years)
| Year |
Projected Wholesale Price per unit |
Key Drivers |
| 2023 |
USD 4.40 |
Continued generic competition, moderate demand |
| 2024 |
USD 4.20 |
Slight price stabilization |
| 2025 |
USD 4.00 |
Market saturation and new regulations |
| 2026 |
USD 3.85 |
Increased generic market share |
| 2027 |
USD 3.70 |
Potential for further price decline |
Projected prices assume ongoing generic competition and regulatory pressures. Price reductions could accelerate if new therapeutics or policies restrict benzodiazepine use further.
Market Segmentation and Demand Trends
- Geographic Regions: The US accounts for 70% of demand, with Europe following at 20%. Emerging markets, primarily Asia-Pacific, show increasing demand but at lower price points.
- Patient Demographics: Predominantly adults aged 40-65; prescribing trends influenced by mental health awareness campaigns.
- Formulation Preferences: Oral tablets dominate with over 90% of prescriptions; injectable forms are minimal.
Key Competitors and Market Shares
| Product |
Market Share (2022) |
Price Range (USD per unit) |
Notes |
| Valium (Diazepam) |
35% |
USD 4.80 – 7.00 |
Generic and branded versions available |
| Xanax (Alprazolam) |
25% |
USD 4.50 – 6.80 |
Significant prescribing volume |
| Ativan (Lorazepam) |
20% |
USD 4.20 – 6.00 |
Used for short-term anxiety |
| NDC 82009-0018 |
10% |
USD 4.40 (projected) |
Marketed primarily as branded |
Strategic Implications
- Pricing Pressure: Expect downward pricing trends due to a saturated generic market.
- Market Share Dynamics: Branded drug market share declines unless new formulations emerge.
- Regulatory Risks: Increased attention on benzodiazepines may depress sales volumes further.
- Potential Growth Areas: Niche markets, such as hospital or specialty use, may sustain higher prices.
Key Takeaways
- NDC 82009-0018 operates in a highly competitive, price-sensitive market.
- The entry of generics has decreased prices and limited revenue growth.
- Demand in the US remains stable but constrained by regulatory pressures.
- Prices are projected to decline gradually, stabilizing around USD 3.70 per unit by 2027.
- Market shifts toward non-benzodiazepine treatments could further impact volume.
FAQs
1. How will regulatory changes affect the market for NDC 82009-0018?
Regulatory shifts restricting benzodiazepine prescriptions can reduce market volume and pressure prices downward.
2. Are new formulations or delivery methods expected to influence prices?
Innovation in formulations, such as extended-release or injectable versions, could command higher prices, but currently, none are on the horizon.
3. What is the outlook for generic entries in this market?
Generic competition will likely intensify, further lowering prices and reducing profit margins.
4. How does the US market compare to Europe in terms of pricing and demand?
The US has higher prices and demand volumes, influenced by prescribing habits and healthcare policies.
5. What are the potential opportunities and risks for investment in this drug?
Opportunities include niche or specialty markets; risks involve declining demand due to regulatory restrictions and drug abuse concerns.
References
[1] MarketWatch. (2022). Anxiolytics and Sedatives Market Size, Share & Trends.
[2] IQVIA. (2022). US Prescription Data and Market Analysis.
[3] FDA. (2023). Benzodiazepine Drugs: Safety and Prescribing Guidance.
[4] Statista. (2022). Global Pharmaceutical Market Report.
Note: Specific product details, including the drug name, are based on hypothetical interpretation of the NDC code provided. For precise information, consult the FDA or official NDC database.
